Indian J Med Microbiol 2021 May 24. Epub 2021 May 24.
Medical Affairs, Pfizer Ltd., The Capital, 18th & 19th Floor, Plot No. C-70, G. Block, Bandra Kurla Complex, Bandra (E), Mumbai, 400051, India.
The efficacy and safety of Ceftazidime-Avibactam (CAZ-AVI) as compared to meropenem for nosocomial pneumonia was established in a randomized, phase-III, non-inferiority trial REPROVE, which included Indian patients. We determined if the results for the Indian patients were in-line with the results of overall population. Descriptive analysis of efficacy and safety demonstrated ceftazidime-avibactam was comparable to meropenem in the management of nosocomial pneumonia in Indian patients and it may be a useful addition to the armamentarium of antibiotics for management of such infections with Enterobacterales and Pseudomonas. Read More